

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> JUL 24 2006 (Use as many sheets as necessary)		<i>Complete if Known</i>	
		Application Number	10/811,130
		Filing Date	03/26/2004
		First Named Inventor	DEVARAJAN et al.
		Art Unit	1653
		Examiner Name	
Sheet 1	of 1	Attorney Docket Number	CHM-015

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)				

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>2</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)					

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s) volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
CF		BLASER, J. et al., A Sandwich Enzyme Immunoassay for the Determination of Neutrophil Lipocalin in Body Fluids, <i>Clinica Chimica Acta</i> , 235 (1995) pp. 137-145	
		<del>MATTHAEUS, T. et al., Co-Regulation of Neutrophil Gelatinase-Associated Lipocalin and Matrix Metalloproteinase-9 in the Postischemic Rat Kidney, <i>Pathophysiology of Renal</i>, A4112, SUI-0348 (PS).</del>	<del>Abstract</del>
CF		MATTHAEUS, T., et al., Acute Ischemic Renal Failure Induces Expression of Neutrophil Gelatinase-Associated Lipocalin and Matrix Metalloproteinase-9 in Damaged Tubuli, <i>Kidney Blood Press Res</i> (2001), Vol. 24, Congress of Nephrology 2001, p 342	Abstract
CF		OHLSSON, S., et al., Increased Circulating Levels of Proteinase 3 in Patients with Anti-Neutrophilic Cytoplasmic Autoantibodies-Associated Systemic Vasculitis in Remission, <i>Clin Exp Immunol</i> (2003), Vol. 131 pp. 528-535	

Examiner Signature	<i>CF</i>	Date Considered	5/17/07
-----------------------	-----------	--------------------	---------


<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary) NOV 16 2006 Sheet 1 of 1				<b>Complete if Known</b>	
				Application Number	10/811,130
				Filing Date	03/26/2004
				First Named Inventor	DEVARAJAN et al.
				Art Unit	1641
				Examiner Name	FOSTER, CHRISTINE E
				Attorney Docket Number	CHM-015

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)				
CF		US-	5,945,294	08-31-1999	Frank et al.	
CF		US-	6,221,625	04-24-2001	Ashihara et al.	
CF		US-	6,664,385	12-16-2003	Sanicola-Nadel et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>2</sup> -Number <sup>2</sup> -Kind Code <sup>2</sup> (if known)					

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s) volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
CF		Biomarkers Definitions Working Group, Biomarkers and Surrogate Endpoints: Preferred Definitions and Conceptual Framework, <i>Clinical Pharm. &amp; Therapeutics</i> , vol. 69, No.3, March 2001, P. 89-95.	
CF		Definition for term "ELISA", <a href="http://www.thefreedictionary.com">www.thefreedictionary.com</a> (1 page), 2/28/2006	
CF		DEVARAJAN, P, Novel biomarkers for the early prediction of acute kidney injury; <i>Cancer Therapy</i> (2005); Vol. 3, pp. 477-488 pages 477-485 and 487	
CF		ELNEIHOUM, A.M., et al., Leukocyte activation in atherosclerosis; correlation with risk factors, <i>Atherosclerosis</i> , 1997 May; 131(1): 79-84	Abstract
CF		HRUBEC et al, Plasma Versus Serum: Specific Differences in Biochemical Analyte Values" <i>Journal of Avian medicine and Surgery</i> 16(2):101-105,2002	
CF		KRAMER, A. A., et al.; Renal ischemia/reperfusion leads to macrophage-mediated increase in pulmonary vascular permeability; <i>Kidney International</i> (1999), Vol. 55; pp. 2362-2367	
CF		Medline Plus Medical Encyclopedia, "Serum Hemoglobin", <a href="http://www.nlm.nih.gov/medlineplus/ency/article/003677.htm">www.nlm.nih.gov/medlineplus/ency/article/003677.htm</a> , 3/1/2006	
CF		RABB, H., et al., Acute renal failure leads to dysregulation of lung salt and water channels; <i>Kidney International</i> (2003); Vol. 63; pp. 600-606	
CF		SCHMIDT-OTT, K. M., et al.; Neutrophil gelatinase-associated lipocalin-mediated iron traffic in kidney epithelia; <i>Current Opinion in Nephrology and Hypertension</i> (2006); Vol. 15:000-000 pp. 1-8	

Examiner Signature	<i>CFoster</i>	Date Considered	5/18/07
--------------------	----------------	-----------------	---------



Attorney Docket No. CHM-015

COPENDING U.S. PATENT APPLICATION				
Examiner Initials*	Applicant(s)	Serial No.	Filing Date	Atty. Docket No.
OK	BARASCH, et al.	11/374,285	10/13/2005	CHM-032

Examiner Signature	Date Considered
<i>Christ</i>	5/18/07



# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/811,130
Filing Date	03/26/2004
First Named Inventor	Prasad Devarajan
Art Unit	1653
Examiner Name	
Attorney Docket Number	CHM-015

Sheet	1	of	2
-------	---	----	---

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)				
CK		US-	4,632,901	12/30/1986	<del>Valkers et al.</del> VALKERS et al.	
CK		US-	4,870,007	09/26/1989	Smith-Lewis	
CK		US-	5,273,743	12/28/1993	Ahlem et al.	
CK		US-	5,656,503	08/12/1997	May et al.	
CK		US-	6,500,627	12/31/2002	O'Connor et al.	

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>2</sup>	Number <sup>2</sup> -Kind Code <sup>2</sup> (if known)				

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s) volume-issue number(s), publisher, city and/or country where published.	T <sup>3</sup>
CK		Muramatsu, Y., Tsujie, M., Kohda, Y., Pham, B., Perantoni, A.O., Zhao, H., Jo, S-K, Yuen, PST, Craig, L., Hu, X., Star, R.A. Early detection of cysteine rich protein 61 (CYR61, CCN1) in urine following renal ischemic reperfusion injury. Kidney Int., 62: 1601-1610, 2002.	
CK		Yoshida, T., Kurella, M., Beato, F., Min, H., Ingelfinger, J.R., Stears, R.L., Swinford, R.D., Gullans, S.R., Tang, S-S. Monitoring changes in gene expression in renal ischemia-reperfusion in the art. Kidney Int., 61: 1646-1654, 2002.	
CK		Supavekin, S., Zhanh, W., Kucheralapati, R., Kaskel, F.J., Moore, L.C., Devarajan, P. Differential gene expression following early renal ischemia-reperfusion. Kidney Int., 63: 1714-1724, 2003.	
CK		Nogae, S., Miyazaki, M., Kobayasji, N., Siato, T., Abe, K., Saito, H., Nakane, P.K., Nakanishi, Y., Koji, T. Induction of apoptosis in ischemia-reperfusion model of mouse kidney: Possible involvement of Fas. J. Am. Soc. Nephrol., 9: 620-631, 1998.	
CK		Daemen, MARC, Van de Ven MWCM, Heineman, E., Buurman, W.A. Involvement of endogenous interleukin-10 and tumor necrosis factor- $\alpha$ in renal ischemia-reperfusion injury. Transplantation, 67: 792-800, 1999.	
CK		Kelly, K.J., Plotkin, Z., Dagher, P.C., Guanosine supplementation reduces apoptosis and protects renal function in the setting of ischemic injury. J. Clin. Invest., 108: 1291-1298, 2001.	
CK		Burne, N.J., Rabb, H. Pathophysiological contributions of fucosyltransferases in renal ischemia reperfusion injury. J. Immunol., 169: 2648-2652, 2002.	
CK		Feldenberg, L.R., Thevananther, S., del Rio, M., DeLeon, M., Devarajan, P. Partial ATP deletion induces Fas- and caspase-mediated apoptosis in MDCK cells. Am. J. Physiol., 276 (Renal physiol 45): F837-F846, 1999.	

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**


(use as many sheets as necessary)

*Complete if Known*

Application Number	10/811,130
Filing Date	03/26/2004
First Named Inventor	Prasad Devarajan
Art Unit	1653
Examiner Name	
Attorney Docket Number	CHM-015

Sheet	2	of	2
-------	---	----	---

CF	Devarajan, P., DeLeon, M., Talasazan, F., Schoenfeld, A.R., Davidowitz, E.J., Burk, R.D. The von Hippel-Lindau gene product inhibits renal cell apoptosis via Bcl-2-dependent pathways. J. Biol. Chem., 276: 40599-40605, 2001.	
CF	Yang, J., Goetz, D., Li, J-Y, Wand, W., Mori, K., Setlik, D., Du, T., Erdjument-Bromage, H., Tempst, P., Strong, R., Barasch, J. An iron delivery pathway mediated by a lipocalin. Mol. Cell., 10: 1045-1056, 2002.	
CF	Molitoris, B.A., Weinberg, J.M., Venkatachalam, M.A., Zager, R.A., Nath, K.A., Goligorsky, M.S. Acute renal failure II. Experimental models of acute renal failure: imperfect but indispensable. Am. J. Physiol. Renal Physiol., 278:F1-F12, 2000.	
CF	Kjeldsen, L., Cowland, J.B., Borregaard, N. Human neutrophil gelatinase-associated lipocalin and homologous proteins in rat and mouse. Biochim. Biophys. Acta, 1482: 272-283, 2000.	
CF	Kjeldsen, L., et al. Characterization of two ELISAs for NGAL, a newly described lipocalin in human neutrophils. J. of Immunological Methods, 198: 155-16, 1996.	
CF	Megyesi, J., Safirstein, R.L., Price, P.M. Induction of p21WAF1/CIP/SD1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure. J. Clin. Invest., 101: 777-782, 1998.	
CF	Shiraishi, F., Curtis, L.M., Truong, L., Poss, K., Visner, G.A., Madsen, K., Nick, H.S., Agarwal, A. Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis. Am. J. Physiol., 278: F726-F736, 2000.	
CF	Ramesh, G., Reeves, W.B. TNF- $\alpha$ mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J. Clin. Invest., 110: 835-842, 2002.	
CF	Mishra, J., Ma, Q., Prada, A., Mitsnefes, M., Zahedi, K., Yang, J., Barasch, J., Devarajan, P. Identification of NGAL as a novel urinary biomarker for ischemic injury. J. Am. Soc. Nephrol., 14: 2534-2543, 2003.	
CF	Tsuruya, K., Ninomiya, T., Tokumoto, M., Hirakawa, M., Masutani, K., Taniguchi, M., Fukuda, K., Kanai, H., Kishihara, K., Hirakata, H., Iida, M. Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death. Kidney Int., 63: 72-82, 2003.	
CF	Bundgaard, J., Sengelov, H., Borregaard, N., Kjeldsen, L. Molecular cloning and expression of a cDNA encoding Ngai: a lipocalin expressed in human neutrophils. Biochem. Biophys. Res. Commun., 202: 1468-1475, 1994.	
CF	Del Rio, M., Imam, A., DeLeon, M., Gomez, G., Mishra, J., Ma, Q., Parikh, S., Devarajan, P. The death domain of kidney ankyrin interacts with Fas and promotes Fas-mediated cell death in renal epithelia. J. Am. Soc. Nephrol., 15: 41-51, 2004.	

Examiner Signature		Date Considered	5/18/07
--------------------	---	-----------------	---------

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

## Complete if Known

Application Number 10/811,130  
Filing Date 03/26/2004  
First Named Inventor DEVARAJAN et al.  
Art Unit 1653  
Examiner Name  
Attorney Docket Number CHM-015

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.¹	Document Number Number - Kind Code² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
CF		US- 5,627,034	05/06/1997	Gould et al.	
CF		US- 5,814,462	09/29/1998	Weinberger	
CF		US- 6,136,526	10/24/2000	Venge	
		US- 6,447,989	09/10/2002	Comper	
CF		US- 6,461,827	10/08/2002	Oda et al.	

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.¹	Foreign Patent Document Country Code³-Number⁴-Kind Code⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Ts
CF		WO 01/55210	08/02/2001	Munin Corporation		
CF		WO 03/068054	08/21/2003	The Government of the United States of America as represented by The Secretary, Department of Health Services		
		WO 2004/005340	01/15/2004	Metagen Pharmaceuticals GMBH		
CF		WO 2004/005544	01/15/2004	Novartis AG		
CF		WO 2005/024054	03/17/2005	Royal Women's Hospital		

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s) volume-issue number(s), publisher, city and/or country where published.	T²
CF		BAILLY, V., et al., Shedding of Kidney Injury Molecule-1, a Putative Adhesion Protein Involved in Renal Regeneration; The Journal of Biological Chemistry, Vol. 277, No. 42, Issue of October 18, pp. 39739-39748, 2002	
CF		CARLSON, M., et al., Human neutrophil lipocalin is a unique marker of neutrophil inflammation in ulcerative colitis and proctitis, Gut 2002; 50:501-506	
CF		EICHLER, I., Human neutrophil lipocalin, a highly specific marker for acute exacerbation in cystic fibrosis, Eur Respir J 1999; 14: 1145-1149	
CF		HAN, W. K., et al., Kidney Injury Molecule-1(KIM-1): A novel biomarker for human renal proximal tubule injury; Kidney International, Vol. 62 (2002), pp. 237-244	
CF		ICHIMURA, T., et al., Kidney Injury Molecule-1 (KIM-1), a Putative Epithelial Cell Adhesion Molecule Containing a Novel Immunoglobulin Domain, is Up-regulated in Renal Cells after Injury, The Journal for Biological Chemistry, Vol. 273, No. 7, Issue of February 13, pp. 4135-4142, 1998	
CF		MALLBRIS, L., et al., Neutrophil gelatinase-associated lipocalin is a marker for dysregulated keratinocyte differentiation in human skin, Experimental Dermatology, Vol. 11, Issue 6 Page 584 - December 2002	Abstract
CF		MISHRA, J., et al, Amelioration of Ischemic Acute Renal Injury by Neutrophil Gelatinase-Associated Lipocalin; J. Am. Soc Nephrol 15:3073-3082, 2004	
CF		MISHRA, J., et al, Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery, The Lancet, Vol. 365, April 2, 2005, pp. 1231-1238	
CF		MISHRA, J., et al., Neutrophil Gelatinase-Associated Lipocalin: A Novel Early Urinary Biomarker for	

CP	Cisplatin Nephrotoxicity, Am J Nephrol 2004; 24:207-315	
----	---	--

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<i>Complete if Known</i>	
				Application Number	10/811,130
				Filing Date	03/26/2004
				First Named Inventor	DEVARAJAN et al.
				Art Unit	1653
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	CHM-015

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s) volume-issue number(s), publisher, city and/or country where published.	T?
CP		ODA, H., et al. Development and Evaluation of a Practical ELISA for human Urinary Lipocalin-Type Prostaglandin D. Synthase, Clinical Chemistry 48:9 1445-1453 (2002)	
		VINAYAK, S., et al., Prevalence of the K76T mutation in the <i>pfcrt</i> gene of <i>Plasmodium falciparum</i> amongst chloroquine responders in India, Acta Tropica, Volume 87, Issue 2, July 2003, pp. 287-293	Abstract
CP		XU, S., Lipocalins as biochemical markers of disease, Biochimica et Biophysica Acta 1482 (2000) 298-307	

Examiner Signature	CP	Date Considered	5/18/07
--------------------	----	-----------------	---------

Attorney Docket No. CHM-015

COPENDING U.S. PATENT APPLICATION				
Examiner Initials*	Applicant(s)	Serial No.	Filing Date	Atty. Docket No.
CK	DEVARAJAN, et al.	11/096,113	03/31/2005	CHM-025M

Examiner Signature	Date Considered
<i>Chen</i>	5/18/07



# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/811,130
Filing Date	March 26, 2004
First Named Inventor	Prasad DEVARAJAN et al.
Art Unit	1653
Examiner Name	
Attorney Docket Number	CHM-015

1 of 1

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
CH		US-	6,447,989	09/10/2002	Comper	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s) volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
CH		LI YAN et al. The High Molecular Weight Urinary Matrix Metalloproteinase (MMP) Activity is a Complex of Gelatinase B/MMP-9 and Neutrophil Gelatinase-associated Lipocalin (NGAL), J. Biol. Chem., 05 October 2001, Vol. 276, No. 40, pages 37258-37265	
CH		MONIER et al., Gelatinase isoforms in urine from bladder cancer patients. Clinica Chimica Acta. September 2000, Vol. 299, (1-2), pages 11-23	
CH		ELNEIHOUM et al. Lukocyte Activation Detected by Increased Plasma Levels of Inflammatory Mediators in Patients with Ischemic Cerebrovascular Diseases. Stroke. (1996), Vol 27, pages 1734-1738	

Examiner  
Signature

CHOST

Date  
Considered

5/18/07